Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
Journal of Clinical Oncology · 2025-03 · 43 (7) · 829-839
DOI: 10.1200/jco.24.00979 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Antonio Avallone und 25 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italia. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Panitumumab, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable RAS / BRAF wild-type (wt) metastatic colorectal cancer (mCRC). PATIENTS AND METHODS IMPROVE (ClinicalTrials.gov identifier: NCT04425239 ) was an open-label, multicenter, randomized phase II noncomparative trial. Patients with unresectable RAS / BRAF wt mCRC were randomly assigned (1:1) to receive FOLFIRI plus PAN continuously until progression (arm A) or intermittently, with treatment-free intervals (arm B) until progression on treatment, toxicity, or death. The primary end point was progression-free survival on treatment (PFSot) at 12 months. Assuming a null hypothesis of median PFSot time ≤7 months and target PFSot ≥10 months, 65 patients per arm were needed to achieve 80% power and 10% type I error, according to the binomial test. RESULTS Between May 2018 and June 2021, 69 patients were randomly assigned to arm A and 68 to arm B. The median number of treatment cycles was 13 in arm A and 16 in arm B. At a median follow-up of 43.2 months (IQR, 35.0-50.5), median PFSot was 11.2 and 17.5 months with 12-month PFSot rates of 45.7% and 58.5%, for arms A and B, respectively. The overall response rates were 68.1% and 61.2%, and median overall survival rates were 36.3 and 35.1 months in arms A and B, respectively. The overall rate of grade >2 skin PAN-related adverse events was 30.3% in arm A and 17.9% in arm B. CONCLUSION Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italia.
- Medical Oncology Irccs Giovanni Paolo II Bari and Medical Oncology San Paolo Hospital ASL, Bari, Italy.
- Oncology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.
- Innovative Therapies Liver Metastases Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italia.
- Medical Oncology Unit, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, Napoli, Italy.
- Medical Oncology Unit, S. Carlo Hospital, Potenza, Italy.
ORCID-Profile: Antonio Avallone, Alfonso De Stefano, Giuseppe Santabarbara, Vincenzo Montesarchio, Gerardo Rosati, Carmela Romano, Claudio Lotesoriere, Alfredo Colombo, Francesco Mannavola, Maria Maddalena Laterza, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, Alfredo Budillon
Zitieren
APA
Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., …, & Budillon, A. (2025). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829-839. https://doi.org/10.1200/jco.24.00979
Vancouver
Avallone A, Giuliani F, De Stefano A, Santabarbara G, Nasti G, Montesarchio V, et al. Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology. 2025;43(7):829-839. doi:10.1200/jco.24.00979
BibTeX
@article{Avallone2025,
author = {Avallone, Antonio and Giuliani, Francesco and De Stefano, Alfonso and Santabarbara, Giuseppe and Nasti, Guglielmo and Montesarchio, Vincenzo and Rosati, Gerardo and Cassata, Antonino and Leo, Silvana and Romano, Carmela and Tamburini, Emiliano and Silvestro, Lucrezia and Lotesoriere, Claudio and Nappi, Anna and Santini, Daniele and Petrillo, Antonella and Colombo, Alfredo and Febbraro, Antonio and Leone, Alessandra and Mannavola, Francesco and Laterza, Maria Maddalena and Izzo, Francesco and Sobrero, Alberto and Delrio, Paolo and Giannarelli, Diana and Budillon, Alfredo},
title = {Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {7},
pages = {829--839},
doi = {10.1200/jco.24.00979}
}
EUVIMED